A detailed history of Assetmark, Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 1,663 shares of IMVT stock, worth $45,749. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,663
Previous 1,639 1.46%
Holding current value
$45,749
Previous $52,000 17.31%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.1 - $31.61 $602 - $758
24 Added 1.46%
1,663 $43,000
Q1 2024

May 06, 2024

BUY
$30.27 - $43.79 $5,509 - $7,969
182 Added 12.49%
1,639 $52,000
Q4 2023

Feb 09, 2024

BUY
$31.31 - $44.19 $45,618 - $64,384
1,457 New
1,457 $61,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.